Nick Paul Taylor

Articles by Nick Paul Taylor

Novartis stock slides as centerpiece of $12B Avidity buyout flunks β€˜crucial’ phase 3 test - Fierce Biotech

Business September 9, 2026

Bristol Myers Squibb inks $15B biobucks deal to bag Hengrui assets, tap China’s R&D speed - Fierce Biotech

Business May 13, 2026

Oruka’s psoriasis data hailed as β€˜outright win over Skyrizi,’ spurring big blockbuster forecasts - Fierce Biotech

Business April 28, 2026

J&J's $5B Alzheimer's hope fades as anti-tau antibody posdinemab flops in phase 2 - Fierce Biotech

Business November 25, 2025

Rocket crashes as gene therapy patient dies, FDA imposes hold - Fierce Biotech

Business May 28, 2025